Adenosine triphosphate injection

Drug Profile

Adenosine triphosphate injection

Alternative Names: ATPace

Latest Information Update: 29 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duska Therapeutics
  • Developer Cordex Pharma
  • Class Adenine nucleotides; Antiarrhythmics; Infertility therapies; Small molecules
  • Mechanism of Action Purinergic P2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bradycardia; Paroxysmal supraventricular tachycardia

Most Recent Events

  • 02 Jun 2009 The US FDA approves Special Protocol Assessment (SPA) design of phase IIb/III trials for Paroxysmal supraventricular tachycardia
  • 20 Feb 2009 Cordex Pharma submits to the US FDA an amended phase III trial protocol for Paroxysmal supraventricular tachycardia
  • 20 Nov 2008 Duska Therapeutics applies for a Special Protocol Assessment with the US FDA to conduct a pivotal phase III trial for Paroxysmal supraventricular tachycardia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top